Opioid Use Disorder
Vaccines Forecast
US opioid overdose deaths have posted their sharpest decline in years, yet remain far above pre-crisis levels, and in early 2026 the first fentanyl-specific vaccine ever entered human trials. This is a comprehensive, wide geography commercial assessment of the opioid use disorder vaccine opportunity, covering the field's inaugural clinical candidate and drawing on VacZine Analytics' long standing, independent authority in addiction vaccine markets.
- Format
- PDF (~140 slides) + Excel workbook
- Coverage
- 8 major western markets
- Scenarios
- 3 patient-pathway access points
- Forecast horizon
- To 2045
- Approach
- Value/volume demand model
- Base edition
- February 2018
- Availability
- Syndicated / bespoke
the second most used drug class
down from 79,358 in 2023
who receive treatment worldwide
the brain, lead vaccine candidate
A crisis in retreat, but still historically severe, and now facing its first vaccine
This review sets out the current disease background, global burden and treatment landscape for opioid use disorder before examining the vaccine candidate that, in 2026, became the first of its kind to enter human trials.
Condition overview - Opioid use disorder (OUD)
Opioid use disorder (OUD) is a chronic, relapsing condition defined by a problematic pattern of heavy, uncontrolled opioid use. In the United States, OUD typically involves either licensed prescription painkillers such as oxycodone and hydromorphone, or illicit drugs such as heroin and synthetic analogues such as fentanyl. Globally, opioids remain the second most widely used drug class after cannabis, with an estimated 60 million users worldwide, part of a wider population of roughly 64 million people with drug use disorders. The treatment gap is severe: only around one in eleven people with drug use disorders receive treatment, a gap that is starker still for women, at roughly one in eighteen.
The United States has borne the sharpest edge of this burden. US opioid overdose deaths rose to a record 79,358 in 2023 before falling to 54,045 in 2024, a decline that provisional data suggest continued through 2025 to around 44,564, driven substantially by a fall in fentanyl-involved deaths. This is genuinely encouraging news, but the numbers remain well above pre-crisis (2019) levels, and the UNODC's World Drug Report 2024 flags the emergence of nitazenes, a class of synthetic opioids that can be even more potent than fentanyl, as a growing threat in several high-income countries. Existing medication-assisted therapies (MAT), methadone, buprenorphine and naltrexone, combined with psychosocial counselling, remain effective for many, but carry safety considerations and are associated with high relapse and discontinuation, and only a fraction of opioid users ever initiate therapy.
Against that backdrop, opioid hapten-conjugate vaccine technology has moved from promising preclinical concept to human reality. An anti-fentanyl vaccine developed at the University of Houston, generating antibodies that bind circulating fentanyl and prevent it from crossing into the brain, blocked up to 98% of fentanyl from reaching the brain in preclinical models. In early 2026, the candidate entered its first human Phase I trial, evaluating safety, tolerability and immune response in healthy adult volunteers, the first fentanyl-specific vaccine ever to be tested in humans. An OUD vaccine of this kind is designed to block the addictive and toxic effects of opioids and reduce relapse, potentially in combination with existing MAT, offering a longer duration of action and better compliance than current small-molecule therapies.
From decades of preclinical research to a first human trial
Opioid hapten-conjugate vaccine research spans decades of preclinical work across multiple opioid targets. The field's first-ever human trial, in a fentanyl-specific candidate, marks a genuine turning point.
-
ARMR Sciences / University of Houston-originatedPhase I/II, challenge study underway Aug 2026Anti-fentanyl vaccine (ARMR-100) Hapten-conjugate
The first opioid-specific vaccine candidate ever to enter human testing. Generates antibodies that bind circulating fentanyl and prevent it crossing into the brain, blocking up to 98% of fentanyl from reaching the brain in preclinical models. Its Phase I/II trial, dosing around 40 healthy adult participants across dose-escalation cohorts, began in early 2026, evaluating safety, tolerability and immunogenicity. On 17 June 2026 developer ARMR Sciences reported topline results across three cohorts (24 participants dosed at that point): anti-fentanyl IgG antibody titers above pre-vaccination baseline at every dose level tested, with no serious adverse events, and the company stated it plans to advance to a fentanyl-challenge study, testing protective efficacy, in Q3 2026. Following a strategic investment from backer SRX Global announced 23 June 2026, ARMR Sciences reported in early September 2026 that dosing had completed across four escalating cohorts, with a booster anti-fentanyl antibody response observed after the second dose and no vaccine-related serious adverse events, and that its first fentanyl-challenge cohort, testing protective efficacy against escalating intravenous fentanyl doses, had begun dosing in late August 2026. The FDA separately accepted the programme into its Model-Informed Drug Development (MIDD) Paired Meeting Program, with an FDA/Department of War meeting scheduled for 3 November 2026. -
Academic & biotech research groupsPreclinical, multiple targetsHeroin, oxycodone & multivalent candidates
A wider field of hapten-conjugate vaccine candidates targeting other opioids and multivalent combinations remains in earlier preclinical development, providing pipeline depth behind the lead fentanyl programme. -
Existing MAT manufacturersApproved, complementary standard of careMethadone, buprenorphine & naltrexone
Established medication-assisted therapies remain the backbone of OUD treatment. A vaccine is positioned as a complement, not a replacement, potentially improving compliance and relapse outcomes alongside MAT. -
UNODC / national public health bodiesSurveillance & harm reductionNitazene & synthetic opioid surveillance
Ongoing monitoring of nitazenes and other emergent synthetic opioids underscores why a durable, preventive tool remains a public health priority even as overdose deaths decline.
2026's dosing of the first human participant in an opioid vaccine trial is a genuine field-first, arriving after decades in which hapten-conjugate vaccine concepts never progressed beyond preclinical models. It lands at a delicate moment: overdose deaths are falling sharply, which could be read as reducing urgency, yet the scale of remaining burden, and the emergence of nitazenes, argues the opposite. The VacZine Analytics model quantifies the commercial opportunity this creates across multiple pipeline-progression and public-health-urgency scenarios.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, current treatment landscape, the R&D competitive picture and scenario-based demand forecasting across 8 major western markets to 2045.
Value/volume demand modelling to 2045 across 8 major western markets, with three scenarios exploring uptake at different points along the treatment continuum.
Full review of the field's first human fentanyl vaccine trial and the wider hapten-conjugate vaccine research landscape.
Target product profile generation, pricing considerations and clinical development feasibility assessment for an OUD vaccine.
Volume and value forecasts to 2045, reflecting the fentanyl vaccine's pipeline progression and alternative public-health-urgency scenarios.
Full global and US burden review, updated with 2024/2025 CDC overdose data and UNODC World Drug Report 2024 findings.
Current MAT treatment landscape, prevention strategies and the business case for a preventive vaccine alongside existing therapies.
A glimpse of the commercial model
The table below shows a partial view of the target-population and scenario framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Target population | Geography | Access point | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| MAT-initiated patients | 8-market model | Maintenance therapy | Pre-licensure | Modelled |
| Justice-involved populations | 8-market model | Post-detoxification | Pre-licensure | Modelled |
| High-risk prescription opioid users | 8-market model | Preventive, early intervention | Pre-licensure | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | 8-market model | All access points | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the business case for an OUD vaccine.
- Executive presentation (~140 slides, PDF) - disease background, global epidemiology, current treatments, prevention strategies and full competitive environment review
- MS-Excel forecast workbook - value/volume outputs to 2045 across 8 major western markets, under three treatment-continuum scenarios
- Vaccine technology review - hapten-conjugate mechanisms, the lead fentanyl-specific candidate, and TPP generation guidance
- Competitor intelligence - the field's first human vaccine trial and the wider preclinical opioid vaccine research landscape
- Updated epidemiology module - 2024/2025 CDC overdose data, UNODC World Drug Report 2024 findings and nitazene emergence
- Pricing & modelling assumptions - fully documented pricing considerations and all underlying model assumptions
Built for organisations weighing the OUD vaccine business case
Designed to inform any party wishing to understand and justify the business case for this important vaccine category, now that a first candidate has entered the clinic.
Vaccine developers
Positioning, TPP and commercial feasibility assessment for opioid-targeted vaccine candidates at any stage.
Corporate strategy & BD
Validate the size and structure of a market with no incumbent vaccine, now that a first candidate has proven human testing is possible.
Investors & analysts
Independent assessment of pipeline risk and commercial upside for due diligence on the first fentanyl vaccine programme and future entrants.
Public health & harm reduction bodies
Demand modelling to support future OUD vaccine programme planning alongside existing MAT and harm reduction infrastructure.
Researchers & academia
Comprehensive epidemiology and R&D landscape for grant, translational and addiction medicine planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public and private channels in 8 major western markets.
VacZine Analytics has tracked addiction vaccine markets since our earliest editions, positioning us to reassess the OUD vaccine opportunity the moment the field's first candidate reached human trials. This is a genuinely comprehensive analysis with a wide geographic focus across 8 major western markets, and it has been well received by clients across the field for the depth of its treatment-continuum and TPP review. Few groups have followed this market as closely, and that recognised, independent expertise underpins everything in the analysis.
This February 2018 edition has been updated to incorporate current CDC overdose data, the UNODC World Drug Report 2024 global burden findings, and the first-ever human trial of a fentanyl-specific vaccine, dosed in early 2026. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc OUD vaccine analysis, a briefing call is included on request.